Chauny

Researchers are studying ways to reduce the duration of immunotherapy treatment in patients with advanced non-small cell lung cancer NSCLC who have their disease controlled after initial treatment. The study focuses on comparing a shorter immunotherapy maintenance period of 6 months to the usual 2 years to see if less treatment can still be effective. This phase II-III randomized study enrolls patients with stage IV NSCLC who have not received prior treatment for advanced disease. Participants will first receive a combination of chemotherapy and pembrolizumab for about 6 months, using specific chemotherapy drugs based on their cancer type. After this induction, patients showing disease control without severe side effects will be randomly assigned to one of two groups continuing pembrolizumab with or without pemetrexed for certain cancer types for up to 2 years or observation with or without pemetrexed. Researchers will monitor various factors including patient characteristics and tumor markers. During the study, participants will attend scheduled visits for treatment and monitoring, including imaging scans to measure tumor response and laboratory tests to check health status. Quality of life and survival will be tracked up to about 24 months after randomization. The study also collects data on side effects and progression-free survival to better understand the benefits and risks of shorter versus longer immunotherapy maintenance.

Researchers are evaluating the impact of virtual reality on managing anxiety, nausea, and vomiting in cancer patients receiving their first line of chemotherapy. This clinical study aims to improve quality of life and assess patient and nursing staff satisfaction during chemotherapy treatment. The study is interventional, randomized, and controlled, involving two groups to compare virtual reality with standard care. Participants are divided into two groups one group experiences a 20-minute virtual reality session during each of the first three chemotherapy cycles, while the other group receives conventional care without virtual reality. These sessions occur during chemotherapy, each lasting more than 30 minutes. The study includes a pre-inclusion visit one week before the first cycle and follow-up visits at 3, 6, and 9 months after completing the three chemotherapy cycles. During the study, participants will complete questionnaires and assessments measuring quality of life, anxiety, pain, fatigue, nausea, and vomiting using tools like the QLQ-C30 questionnaire, Visual Analogue Scale VAS, and MASCC Antiemesis Tool MAT. Patient and nurse satisfaction will be evaluated after chemotherapy sessions. Vital signs such as heart rate and blood pressure will be monitored. The total study duration includes chemotherapy cycles plus follow-up visits extending up to nine months post-treatment.